News
Stonegate Research Report on Incannex Healthcare Inc.
Health & Biotech Stonegate Research Report on Incannex Healthcare Inc....
Stonegate Initiates Coverage on Incannex Healthcare Inc.
Health & Biotech Press release: Stonegate Initiates Coverage on Incannex Healthcare Inc. (NasdaqGM:IXHL)...
The progress of the RePOSA Study
Health & Biotech More Drug Does Not Always Lead to More Efficacy: Dr Mark Bleackley on the Progress...
Sleep Apnea Drug Candidate – Dosing Completed
Health & Biotech Dosing Completed in 115 Participant Bioavailability/Bioequivalence Clinical Trial for Proprietary Sleep Apnea Drug Candidate...
FDA Review of PsiGAD2 IND Complete
Health & Biotech FDA Review of PsiGAD2 IND Complete; Clinical Trial for Psilocybin-Assisted Psychotherapy in Patients With Generalized...
Incannex Healthcare gets FDA nod for Phase 2 trial
Health & Biotech The trial is studying the effects of psilocybin on patients with generalized anxiety disorder...
4 Psychedelic Stocks to Consider as Clinical Trials Heat up
Health & Biotech 4 Psychedelic Stocks to Consider as Clinical Trials Heat up...
Dr Mark Bleackley Addresses Lack of OSA Pharmacotherapies, Need for IHL-42X
Health & Biotech Dr Mark Bleackley Addresses Lack of Pharmacotherapies in OSA, Need for IHL-42X...
Joel Latham – A promising new combination Therapy for OSA
Health & Biotech Joel Latham talks to DocWire on a promising new combination Therapy for (OSA) Obstructive Sleep...
IHL-42X Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial
Health & Biotech Patient dosing commenced in RePOSA Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in...
Joel Latham talks to Jane King about a potential (OSA) treatment
Health & Biotech Frontiers of Healing: Joel Latham’s Quest to Transform Modern Medicine...
Joel Latham’s Quest to Transform Modern Medicine
Health & Biotech Frontiers of Healing: Joel Latham’s Quest to Transform Modern Medicine...
Psi-GAD1 Positive Topline Results from Phase 2 Clinical Trial
Health & Biotech Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised...
Phase 2 “PsiGAD” Clinical Trial Dosing and Therapy Complete
Health & Biotech Incannex Completes Dosing and Therapy in Phase 2 "PsiGAD" Clinical Trial Assessing Psilocybin-assisted Psychotherapy for...
Clarion Clinics receives ethical endorsement
Health & Biotech How Melbourne psychedelic treatment clinic 'Clarion Clinics' on Yarra River front will work. Australia’s first...
Top 20 Shareholder Report October 2023
Health & Biotech Top 20 shareholder report as of October 16, 2023....
FDA clearance to start IHL-42X clinical trial with OSA patients
Health & Biotech Incannex Healthcare (ASX: IHL) has received approval from the US Food and Drug Administration (FDA) to...
FDA application prepared: Psilocybin-assisted psychotherapy program
Health & Biotech Incannex Healthcare (ASX: IHL) subsidiary Psychennex Pty Ltd has started preparing an investigational new drug (IND)...
Clarion Clinics ready to open
Health & Biotech Incannex Healthcare’s (ASX: IHL) subsidiary, Clarion Clinics Group, has begun accepting registrations of interest from...
Positive pre-IND meeting for IHL-675A arthritis treatment
Health & Biotech Chief scientific officer Dr Mark Bleackley tells Proactive about its positive pre-IND meeting for IHL-675A...
Key application submitted to FDA for $15bn sleep apnoea market
Health & Biotech Key application submitted to FDA for new treatment in $15 billion sleep apnoea market...
Ethics approval: Phase 2 clinical trial – rheumatoid arthritis
Health & Biotech Incannex has been given the green light to start its Phase 2 clinical trial to...
IHL-42X (OSA) bioequivalence/bioavailability ethic approval
Health & Biotech Incannex has received approval from Bellberry Human Research Ethic Committee ('HREC') to commence the bioequivalence/bioavailability...
Lead investigators appointed for clinical trial into sleep apnoea
Health & Biotech Special Report: Incannex Healthcare has recruited two highly experienced lead principal investigators (PIs) for the...
World renowned psychedelic experts join Clarion Clinic’s board
Health & Biotech Special Report: Incannex Healthcare has announced that three of the world’s top psychedelic therapy and science...
90 Seconds With Peter Widdows
Health & Biotech Got 90 seconds? Then listen to Director, Peter Widdows tell us about their company news....
Psychennex to open psychedelic clinics and capture opportunity
Health & Biotech Special Report: Incannex’s psychedelics focused subsidiary, Psychennex, believes that it has the best team of...
Australia’s first psychedelic-assisted psychotherapy clinic
Health & Biotech Special Report: Incannex Healthcare’s subsidiary Clarion Clinics will be the first dedicated psychedelic-assisted psychotherapy business...
Anti-inflammatory drug (IHL-675A) well tolerated in Phase-1 trial
Health & Biotech Special Report: Results from a Phase-1 clinical of Incannex’s anti-inflammatory drug IHL-675A in healthy volunteers...
Incannex fast tracks products for addiction and skin diseases
Health & Biotech Special Report: Incannex has made a key appointment as it works to advance its CannQuit-N...
Incannex to open psychotherapy clinic with leading experts
Health & Biotech Special Report: IHL is undergoing a pivotal point in its journey as a company moving...
Notable benefit for psilocybin over placebo when treating anxiety
Health & Biotech Special Report: Even though specific data from the PsiGAD trial cannot yet be released until...
Incannex kicks off Phase 2 rheumatoid arthritis trial
Health & Biotech Incannex CEO Joel Latham tells Proactive the company has begun a Phase 2 clinical trial,...
Psilocybin locked-in for trials and potential commercialisation
Health & Biotech Incannex has reached another milestone in progressing its psilocybin drug product by engaging Catalent to...
Commencing manufacture of psilocybin for commercial applications
Health & Biotech Special Report: As Australia becomes the first country to recognise psychedelics as medicine, Incannex Healthcare...
Phase 2 trial commences for treatment of rheumatoid arthritis
Health & Biotech Incannex commences phase 2 trial assessing IHL-675A for treatment of rheumatoid arthritis....
TGA allows psilocybin and MDMA for treating depression and PTSD
Health & Biotech Australia leads the way as TGA allows psilocybin and MDMA for treating depression and PTSD....
Incannex at forefront of psychedelic research and development
Health & Biotech Independent analysis has started of Incannex’s Phase 2 clinical trial to assess its psilocybin-assisted psychotherapy...
CEO Joel Latham speaks with Proactive after raising A$13 million
Health & Biotech Watch Incannex CEO Joel Latham speak with Proactive after raising A$13 million in a placement...
Incannex files patent to expand IHL-42X intellectual property
Health & Biotech Incannex Healthcare Ltd (ASX:IHL, NASDAQ:IXHL) has filed a provisional patent application for additional protection of...
Eurofins to manufacture Incannex’s topical cannabinoid formulation to treat common skin conditions
Health & Biotech Clinical stage pharmaceutical cannabinoid and psychedelics company Incannex has engaged Eurofins to manufacture ReneCann Therapeutic Topical...
Incannex appoints Eurofins to manufacture novel addiction treatments CannQuit-N and CannQuit-O
Health & Biotech Incannex is teaming with Eurofins to help people with opioid and nicotine addiction disorders, by...
Incannex initiates big clinical trial and details FDA plans for pivotal clinical trials for sleep apnoea drug
Health & Biotech Special Report: Incannex Healthcare commits to a 116-person bioavailability/ bioequivalence (BA/BE) study and will submit...
Incannex completes US FDA meeting for IHL-216A in treating traumatic brain injury
Health & Biotech Incannex Healthcare completes US FDA meeting for IHL-216A in treating traumatic brain injury. The US...
Incannex advance – Phase 2 clinical trials anti-inflammatory drug
Health & Biotech Special Report: After completing patient dosing in its Phase 1 clinical trial of anti-inflammatory IHL-675A,...
Dronabinol Is a Strong Contender for the First Sleep Apnea Pill
Health & Biotech Dronabinol, synthetic THC, shows promise for the treatment of sleep apnea, and new advances from...
IHL share price climbs before debuting on S&P/ASX 300 index
Health & Biotech The post IHL share price climbs before debuting on S&P/ASX 300 index appeared first on...
Incannex attracts global regulatory affairs expert, Novo Nordisk
Health & Biotech Incannex has appointed a former Pfizer and now Novo Nordisk A/S executive to its board...
Incannex powers into addiction treatment following APIRx deal
Health & Biotech Incannex will move into the lucrative treatment of drug addictions following its takeover of APIRX....
Incannex completes landmark deal as a global leader
Health & Biotech Incannex has completed a landmark acquisition which strengthens its global leadership in the cannabinoid and...
Incannex receives key ethics approval to start Phase 1 clinical trial of multi-use anti-inflammatory drug
Health & Biotech Special Report: Incannex has achieved approval to start a milestone clinical trial into its multi-use,...
Incannex IHL-42X lowered apnoea hypopnea index score in OSA
Health & Biotech Incannex Healthcare’s IHL-42X lowered apnoea hypopnea index score in OSA sufferers during clinical study. During a...
Incannex meets with US FDA on development of IHL-42X
Health & Biotech Clinical-stage cannabinoid pharmaceutical development company Incannex Healthcare (ASX: IHL) has completed a pre-investigational new drug...
Australia’s top 20 cannabis companies
Health & Biotech After its share price hit an all-time high in early 2022, the newly joint-listed medicinal...
Shares in Incannex jump 11% after positive US FDA meet over sleep apnoea drug
Health & Biotech Special Report: In another significant milestone, Incannex Healthcare (ASX:IHL) says it’s received positive feedback with...
Incannex shares reach a high of 44c on landmark $125m deal to buy US cannabinoid pioneer APIRx
Health & Biotech Special Report: Incannex shares have rocketed higher today on news it has signed a formal...
Knocking heads: Incannex achieves key concussion breakthrough
Health & Biotech Special Report: IHL’s novel drug IHL-216A could be the holy grail in concussion treatment, with...
With $40m in the bank and an exciting product suite, Incannex targets game-changing US acquisition for even more growth
Health & Biotech Special Report: The company had a busy quarter of clinical research breakthroughs, listing on NASDAQ...
Incannex announces big clinical trial results – IHL-42X drug reduced key obstructive sleep apnoea diagnostic measure by up to 91.5%
Health & Biotech The medicinal cannabis and psychedelic clinical development company has achieved a significant milestone for both...
Severe anxiety disorders to get the Incannex, Monash Uni treatment via psychedelics within virtual reality
Health & Biotech Incannex and Monash University will collaborate on ground-breaking research to advance treatment for severe forms...
Incannex Rings the Nasdaq Stock Market Closing Bell
Health & Biotech Incannex Healthcare Limited (Nasdaq: IXHL), a clinical stage pharmaceutical development company visits the Nasdaq MarketSite...
Incannex hits the Nasdaq for a wider audience
Health & Biotech Special Report: The bell has rung on Incannex’s much anticipated Nasdaq listing with the company...
Cannabinoid-Based Medicines Leading the Next Wave of Healthcare Solutions
Health & Biotech To fill the gap in the medical space, Incannex combined cannabinoids with generic drug products...
Healthcare has been a hot sector. Here are the top ASX biotech stocks in 2021
Health & Biotech The life sciences sector has emerged into the spotlight ever since the pandemic began. In...
What’s the best pot stock of 2021? And who’s targeting market domination in 2022?
Health & Biotech The Australian medicinal cannabis market has seen strong growth in 2021, with revenue from product...
Incannex completes Phase 2 trial for its cannabinoid drug for sleep apnea, flags Nasdaq listing in January 2022
Health & Biotech Special Report: With Phase 2 dosing complete, IHL now prepares to file a pre-IND meeting...
ASX Health Stocks: Emyria to create wearable device for psychedelics, while Telix gets FDA nod
Health & Biotech The ASX 200 Health Index (XHJ) is trading higher by 0.92% at the time of...
As Biotron more than doubles on promising COVID results, which other ASX stocks are working on treatments?
Health & Biotech One of the few bright spots in ASX Covid news in the past week, amidst...
Interview: Head of Australia’s First Psychelic Lab
Health & Biotech Recently, we wrote about a ground-breaking study being conducted by Monash University that aims to...
Weed Week: Cannabis advent calendars and US Republicans introduce weed bill for veterans
Health & Biotech Instead of a chocolate advent calendar this year, Californians can get their hands on a...
IHL’s psilocybin treatment takes 2 steps forward, with a boost from the FDA and ethics approval to commence trials at Monash University
Health & Biotech Special Report: The world-first treatment is on track to commence clinical trials in early 2022....
Incannex Healthcare moves forward with soft gel capsule design for IHL-42X to treat obstructive sleep apnoea
Health & Biotech Special Report: Cannabinoid and psychedelic biotech company Incannex Healthcare (ASX: IHL) has engaged Colombian-based manufacturer...
ASX Health Stocks: Truscreen jumps 38% on business update, flagging strong growth in China
Health & Biotech The ASX 200 Health Index (XHJ) is up by 1.2% at the time of writing,...
Dr Boreham’s Crucible: 4 ASX stocks focused on a mind-altering $25 billion psilocybin market
Health & Biotech With more than 120 trials in the last decade, and a potential $25 billon market,...
The TGA could soon relax rules on psychedelics. Here are the ASX stocks that could benefit
Health & Biotech After decades of being stigmatised and shunned, psychedelic drugs are making a comeback. The Australian...
CBD Oil: The ultimate investor’s guide to a potential $64 billion global market
Health & Biotech Cannabis has been used as medicine for thousands of years. Ancient Indian, Chinese, and Egyptian...
Check Up: Dimerix and ImpediMed announced breakthroughs, while earnings dominate news flow in August
Health & Biotech Although earnings results were the main theme in August, there were also some notable healthcare...
Weed Week: Cannabis trade shows and Europe imports medicinal marijuana
Health & Biotech Virginia is the latest US state to legalise marijuana and they’re celebrating with the first...
Incannex sets sights on US capital markets and prepares for a Nasdaq listing
Health & Biotech Special Report: Incannex lodged extensive registration form with SEC. A strategic dual-listing will give Incannex...
ASX health stocks: CSL leads another round of strong earnings, but FY22 outlook remains subdued
Health & Biotech The ASX 200 health stocks index (XHJ) fell by 0.76% this morning, compared to the...
Rise and Shine: What you need to know before the ASX opens
Health & Biotech On Stockhead today, the stock that has soared 10,000pc, all you need to know about...
Weed Week: Cannabis ice cream deal and Israeli CBD market worth US$475m by 2025
Health & Biotech Massachusetts based MariMed has just announced a joint collaboration with a legendary ice cream brand...
ASX health stocks: Rhinomed rockets 80% after securing first government purchase for COVID-19 Rhinoswabs
Health & Biotech The ASX200 health stocks index (XHJ) fell by 0.13% this morning, compared to the broader...
IHL’s global research team lays out the blueprint for its psilocybin therapy development pathway, shares climb
Health & Biotech Special Report: The company’s latest update clearly illustrates the rigorous testing approach adopted by IHL’s...
ASX health stocks: EMV’s brain scanner is completed and ready for testing, stock price jumps 16pc
Health & Biotech The ASX200 health stocks index (XHJ) fell by 0.14% this morning, compared to the broader...
Market Highlights and 5 ASX Small Caps to watch on Tuesday
Health & Biotech Wall Street mixed as oil and metals fall US stock markets were mixed on Monday,...
A busy Q4 shows how Incannex Healthcare is laying the foundations for its clinically backed global growth strategy
Health & Biotech Special Report: The June quarter demonstrated IHL’s ability to execute on a multi-channel development strategy....
Incannex kicks off Phase 1 clinical trial for its anti-inflammatory treatment
Health & Biotech Special Report: Along with Phase 1 trials for IHL-675A, the company also received a positive...
ASX health stocks: Proteomics jumps 10% on blood test deal with Nasdaq-listed Abcam
Health & Biotech The ASX Healthcare index fell slightly by 0.17% this morning, compared with the broader index...
Incannex files global patent for its IHL-42X sleep apnoea treatment and receives ethics approval to administer to patients every day in an extension trial
Health & Biotech Special Report: IHL is on track to obtain clinical results from its Phase 2b trial...
ASX health stocks: AusCann (ASX:AC8) up 5pc after asking for approval of cannabis-based canine drug
Health & Biotech The ASX Healthcare index rose by 0.45% this morning, compared with the broader index which...
Incannex secures complete supply chain solution for its anti-inflammatory multi-use drug
Health & Biotech Special Report: Incannex has engaged Procaps to develop and manufacture its IHL-675A soft-gel capsules in...
Market highlights and 5 ASX small caps to watch on Friday
Health & Biotech Wall Street mixed as F45 makes US IPO debut There was no clear direction in...
Australia’s top 20 cannabis companies
Health & Biotech Investing in the medicinal cannabis industry is not for the faint-hearted. As 2020 has shown,...
Why this hidden gem in the Incannex product suite could be a global market winner
Health & Biotech Special Report: The company now has a targeted research pathway to clinical success, with strong...
Global pharma leader Vectura will help Incannex develop its concussion treatment drug
Health & Biotech Special Report: The deal gives IHL a global partner to develop the drug and navigate...
Market highlights and 5 ASX small caps to watch on Monday
Health & Biotech Wall Street plummets on ‘Triple Witching day’ All major US indices fell on Friday, mostly...
US growing approvals a ‘monumental’ step away from Trump moratorium on pot licensing
Health & Biotech Last week the US government announced it would begin granting growing approvals to several companies...
Incannex takes key step towards FDA approval for IHL-42X with new research partnership
Health & Biotech Special Report: The company has partnered with one of Australia’s leading sleep science research as...
Market highlights and 5 ASX small caps to watch on Tuesday
Health & Biotech Tech stocks fell hard on the eve of US CPI report All major indices fell...
Incannex highlights Q1 momentum with 4C update, shares rally again
Health & Biotech Special Report: The company is moving from strength to strength as it builds out its...
US banks closer to legally doing business with cannabis, as ASX-listed Incannex pushes its way into the country
Health & Biotech The US cannabis market reacted in jubilation last week, after the Secure and Fair Enforcement...
How Incannex is positioning to be the ‘next GW Pharma’, with CEO Joel Latham
Health & Biotech Special Report: Incannex provides investors the best of breed for medicinal cannabis and psychedelic therapy...
Hot Pot Stocks: Here are 8 ASX plays that have tripled in the last 12 months
Health & Biotech ASX pot stocks have run hot in recent months but eight in particular have been...
Weed Week: 4/20 can’t help ASX cannabis companies
Health & Biotech April 20 has come and gone, but ASX cannabis companies aren’t getting that high —...
Incannex gets more good news, as FDA approves expanded development pathway for its IHL-675 treatment
Health & Biotech Special Report: Incannex Healthcare (ASX:IHL) continues to execute on its multi-channel development pathway for clinically-proven...
Incannex granted meeting with FDA over CBD drug cocktail
Health & Biotech Special Report: Incannex Healthcare (ASX:IHL) is making steady progress on its hydroxychloroquine (HCQ)/cannabidiol (CBD) drug...
Incannex will pursue a SIXTH possible use for its experimental drug cocktail: treating rheumatoid arthritis
Health & Biotech Special Report: Incannex Healthcare (ASX:IHL) hydroxychloroquine/cannabidiol (CBD) cocktail is turning into a veritable wonder drug...
Rise and Shine: What you need to know before the ASX opens
Health & Biotech On Stockhead today, should nickel bulls be worried about Tsingshan’s big move, details of China’s five-year...
Rise and Shine: What you need to know before the ASX opens
Health & Biotech On Stockhead today, who’s going to solve WA’s gas problem, 10 stocks that went 20-bag after Covid,...
Incannex teams up with Monash University and the NFL in exciting new study for its proprietary concussion treatment
Health & Biotech Special Report: The new study could accelerate the pathway to Phase 2 clinical trials for...
Market highlights and 5 ASX small caps to watch on Thursday
Health & Biotech Wall Street rallied again Stocks on Wall Street rallied for the second day in a...
So, COVID vaccines are here; what now for all those biotechs working on COVID 19 drugs or tests?
Health & Biotech COVID-19 vaccines have reached Australia but ASX stocks that were making anti-COVID 19 drugs or...
Incannex says its experimental drug cocktail might work to treat inflammatory bowel disease
Health & Biotech Special Report: Incannex Healthcare (ASX:IHL) has found a fifth possible use for its hydroxychloroquine/cannabidiol (CBD)...Subscribe and stay connected
Stay up to date with Incannex’s leading research and development programs, multiple secondary assets, investor relations and biotechnology advancements.
"*" indicates required fields